Severe liver dysfunction after raltitrexed administration in an HCV-positive colorectal cancer patient.
Santini
D
D
Picardi
A
A
Vincenzi
B
B
Binetti
P
P
Massacesi
C
C
La Cesa
A
A
Tonini
G
G
D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D003082:Colectomy / Q000379:methods; D003110:Colonic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000556:secondary / Q000601:surgery; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects*; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects*; D014766:Viremia / Q000150:complications
D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D016898:Interferon-alpha; D009944:Organoplatinum Compounds; D011799:Quinazolines; D013876:Thiophenes; D000077150:Oxaliplatin; C068874:raltitrexed